Startside500124 • BOM
add
Dr Reddy's Laboratories Ltd
Forrige sluttkurs
1 194,55 ₹
Dagsintervall
1 194,00 ₹ - 1 222,85 ₹
Årsintervall
1 074,35 ₹ - 1 420,20 ₹
Markedsverdi
1,01 bill. INR
Gjennomsnittlig volum
59,31k
P/E-tall
18,98
Utbytte
0,66 %
Hovedbørs
NSE
Markedsnyheter
Økonomi
Resultatregnskap
Omsetning
Nettoomsetning
(INR) | sep. 2024info | Endring år til år |
---|---|---|
Omsetning | 80,16 mrd. | 16,51 % |
Driftskostnader | 29,72 mrd. | 24,54 % |
Nettoomsetning | 12,55 mrd. | −15,18 % |
Netto resultatmargin | 15,66 | −27,20 % |
Fortjeneste per aksje | 15,83 | −11,13 % |
EBITDA | 22,02 mrd. | 8,53 % |
Faktisk avgiftssats | 30,01 % | — |
Balanseregnskap
Totale aktiva
Totale passiva
(INR) | sep. 2024info | Endring år til år |
---|---|---|
Kontant / kortsiktige inv. | 63,07 mrd. | −7,15 % |
Totale aktiva | 465,96 mrd. | 34,27 % |
Totale passiva | 156,67 mrd. | 66,79 % |
Total egenkapital | 309,28 mrd. | — |
Utestående aksjer | 833,05 mill. | — |
P/B-forhold | 3,26 | — |
Avkastning på aktiva | 10,24 % | — |
Avkastning på kapital | 13,21 % | — |
Kontantstrøm
Netto kontantstrøm
(INR) | sep. 2024info | Endring år til år |
---|---|---|
Nettoomsetning | 12,55 mrd. | −15,18 % |
Kontantstrøm fra drift | 9,32 mrd. | −48,03 % |
Kontanter fra investering | −19,07 mrd. | −322,21 % |
Kontanter fra finansiering | 16,15 mrd. | 329,53 % |
Netto kontantstrøm | 6,37 mrd. | 1,03 % |
Fri kontantstrøm | 3,92 mrd. | −72,47 % |
Om
Dr. Reddy's Laboratories is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
Administrerende direktør
Grunnlagt
1984
Hovedkvarter
Nettsted
Ansatte
27 048